Insulin aspart faster-acting - Novo Nordisk

Drug Profile

Insulin aspart faster-acting - Novo Nordisk

Alternative Names: FIAsp; Fiasp; NN-1218

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 12 Sep 2017 Updated efficacy data from the phase III Onset® 1 trial in Type-1 diabetes mellitus presented at the 53rd European Association for the Study of Diabetes Annual Meeting (EASD-2017)
  • 16 Aug 2017 Novo Nordisk completes the phase III onset®8 trial in Type-1 diabetes mellitus (Combination therapy) in USA, Austria, Bulgaria, Canada, Germany, India, Israel, Italy, Japan, Puerto Rico, Russia, Serbia and Taiwan (SC) (NCT02500706)
  • 13 Jul 2017 Novo Nordisk initiates enrolment in a phase III trial for Type-2 diabetes mellitus in Spain (EudraCT2016-000878-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top